Josh Allen, PhD and SVP of Research and Development at Oncoceutics will be presenting ONC201 at 2018 Experimental Biology in San Diego, April 21 – 25. The presentation will discuss the role of DRD2 in oncology and speak about the ability of imipridones to target GPCRs with a high degree of selectivity. ONC201, the founding
Oral talk 1 in section ‘GPCR-Targeted Drug Design’ Varun Prabhu: Anti-Leukemic Activity of Imipridone ONC212 via Selective Targeting of Orphan GPCR GPR132/G2A Tuesday, April 3, 2:20 pm | Hilton Bayfront | San Diego, California Oral talk 2 in section ‘Small Molecules for Cancer Immunotherapy’ Josh Allen: The Imipridone ONC201, a Selective DRD2 Antagonist, Exerts Immunostimulatory Activity
ONC201 to be discussed at the Keystone Symposia on Molecular and Cellular Biology on February 20, 2018 Josh Allen of Oncoceutics will be giving a Short Talk under the title of “Differentiated Receptor Pharmacology of Imipridone ONC201: The First DRD2 Antagonist in Clinical Development for Oncology”. The Short Talk is part of the Keystone Symposia
Dr. Benjamin Free, a collaborator with Oncoceutics on the effects of ONC201 and ONC206 on the dopamine receptor, will be presenting his research at the University City Science Center as part of the Science Center’s Lunch for Hungry Minds program. While blockade of the D2 dopamine receptor (D2R) is known to be required and primarily
Business Development